The early diagnosis of cutaneous T-cell lymphomas (CTCL) may be challenging and based on a combination of clinical, biological, histological, and molecular criteria (1). View the full article @ The …
Proof-of-concept for clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase 2 BELIEVE study.
Bruton tyrosine kinase (BTK) inhibition targets B-cell and other non-T-cell immune cells implicated in pemphigus pathophysiology, an autoimmune disease driven by anti-desmoglein autoantibodies. Rilzabrutinib is a new reversible, covalent BTK …
Reporting of randomized controlled trial abstracts in dermatology journals according to CONSORT guidelines.
Clinicians often only read the abstracts of studies1,2 so accurate and complete reporting of randomized clinical trial (RCT) abstract is essential. The Consolidated Standards of Reporting Trials extension for Abstracts …
Article Topic/Title: Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome. Part II: Prognosis and Management.
Primary cutaneous T-cell lymphomas (CTCLs) other than Mycosis Fungoides (MF) and Sézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical course, prognoses, and management. With morphologic …
Single-parenthood and health conditions among children receiving public assistance in Japan: a cohort study.
Children’s healthy development is important. While governmental public assistance benefits financially troubled families, it cannot compensate for a lack of social support. Single-parenthood is a health risk factor for children …
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Combination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and …